Home
IMRX
IMRX News

Latest Immuneering Corporation (IMRX) News on December 18, 2024

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

GlobeNewswire

a day ago

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Benzinga

5 days ago

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

MT Newswires

5 days ago

Morgan Stanley Downgrades Immuneering to Underweight From Equalweight, Removes $4 Price Target, Sets Base Case Range of $1-$5

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

GlobeNewswire

6 days ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

GlobeNewswire

21 days ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor

Simply Wall St.

a month ago

Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

a month ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug

Zacks

2 months ago

IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug

MT Newswires

2 months ago

Immuneering Says Potential Pancreatic Cancer Treatment Gets FDA Orphan Drug Designation

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

GlobeNewswire

2 months ago

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation

Simply Wall St.

2 months ago

Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study

Zacks

3 months ago

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study

MT Newswires

3 months ago

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday

Why Is Nanocap Immuneering Stock Trading Higher On Friday?

Benzinga

3 months ago

Why Is Nanocap Immuneering Stock Trading Higher On Friday?

MT Newswires

3 months ago

Top Premarket Gainers

MT Newswires

3 months ago

Chardan Raises Price Target on Immuneering to $13 From $12, Maintains Buy Rating

MT Newswires

3 months ago

Update: Immuneering Shares Surge Premarket as 'Positive' Data Seen in Phase 2a Pancreatic Cancer Trial

MT Newswires

3 months ago

Immuneering Shares Surge After 'Positive' Data in Phase 2a Pancreatic Cancer Trial

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

GlobeNewswire

3 months ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire

4 months ago

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Favourable Signals For Immuneering: Numerous Insiders Acquired Stock

Simply Wall St.

4 months ago

Favourable Signals For Immuneering: Numerous Insiders Acquired Stock

MT Newswires

4 months ago

Chardan Adjusts Immuneering Price Target to $16 From $12, Maintains Buy Rating

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

4 months ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

GlobeNewswire

5 months ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 06/18/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 06/17/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 06/14/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 06/13/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 06/12/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 06/11/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 06/10/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 06/07/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 06/06/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 06/05/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 06/04/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 06/03/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/31/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/30/2024

Immuneering to Present at the Jefferies Global Healthcare Conference

GlobeNewswire

7 months ago

Immuneering to Present at the Jefferies Global Healthcare Conference

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/29/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/28/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/24/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/23/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/22/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/21/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/20/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/17/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/16/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/15/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/14/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/13/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/10/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/09/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/08/2024

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

7 months ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

We Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth Carefully

Simply Wall St.

7 months ago

We Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth Carefully

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/07/2024

Immuneering Recognizes Melanoma Awareness Month

GlobeNewswire

7 months ago

Immuneering Recognizes Melanoma Awareness Month

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 05/06/2024

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 05/03/2024

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 05/02/2024

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 05/01/2024

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 04/30/2024

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 04/29/2024

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 04/26/2024

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 04/25/2024

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 04/24/2024

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 04/23/2024

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

GlobeNewswire

8 months ago

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire

8 months ago

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

GlobeNewswire

9 months ago

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering Director Acquires 7.5% More Stock

Simply Wall St.

9 months ago

Immuneering Director Acquires 7.5% More Stock

Immuneering (IMRX) Plummets 71% in One Week: Here's Why

Zacks

9 months ago

Immuneering (IMRX) Plummets 71% in One Week: Here's Why

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

GlobeNewswire

9 months ago

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

GlobeNewswire

9 months ago

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

GlobeNewswire

9 months ago

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

GlobeNewswire

9 months ago

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

GlobeNewswire

9 months ago

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

GuruFocus.com

10 months ago

Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

GlobeNewswire

10 months ago

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

GlobeNewswire

10 months ago

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave

InvestorPlace

10 months ago

3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave

Immuneering Announces Participation in February Investor Conferences

GlobeNewswire

a year ago

Immuneering Announces Participation in February Investor Conferences

Thomson Reuters StreetEvents

a year ago

Q2 2024 LSI Industries Inc Earnings Call

LSI Industries Inc. (LYTS) Reports Q2 Fiscal 2024 Results: Net Income Dips Slightly Amidst ...

GuruFocus.com

a year ago

LSI Industries Inc. (LYTS) Reports Q2 Fiscal 2024 Results: Net Income Dips Slightly Amidst ...

Analysts Are Updating Their Citizens & Northern Corporation (NASDAQ:CZNC) Estimates After Its Full-Year Results

Simply Wall St.

a year ago

Analysts Are Updating Their Citizens & Northern Corporation (NASDAQ:CZNC) Estimates After Its Full-Year Results

ChargePoint Becomes One of the First EV Charging Providers to Receive FedRAMP Approval for the Implementation of Federal EV Charging Infrastructure

Business Wire

a year ago

ChargePoint Becomes One of the First EV Charging Providers to Receive FedRAMP Approval for the Implementation of Federal EV Charging Infrastructure

Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx

Zacks

a year ago

Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx

Pinstripes Holdings, Inc. Rings the NYSE Opening Bell Today and Reports Preliminary Unaudited Fiscal 2024 Third Quarter Sales Results

Business Wire

a year ago

Pinstripes Holdings, Inc. Rings the NYSE Opening Bell Today and Reports Preliminary Unaudited Fiscal 2024 Third Quarter Sales Results

Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases

GlobeNewswire

a year ago

Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases

Forum Energy Technologies to Present at the Sidoti Virtual Investor Conference

Business Wire

a year ago

Forum Energy Technologies to Present at the Sidoti Virtual Investor Conference

Ceva and THX Ltd. Partner to Bring Premium Spatial Audio to Hearables, Consumer and Mobile Products

PR Newswire

a year ago

Ceva and THX Ltd. Partner to Bring Premium Spatial Audio to Hearables, Consumer and Mobile Products

With 37% ownership, Immuneering Corporation (NASDAQ:IMRX) has piqued the interest of institutional investors

Simply Wall St.

a year ago

With 37% ownership, Immuneering Corporation (NASDAQ:IMRX) has piqued the interest of institutional investors

Rimini Street (NASDAQ:RMNI) shareholders have endured a 35% loss from investing in the stock five years ago

Simply Wall St.

a year ago

Rimini Street (NASDAQ:RMNI) shareholders have endured a 35% loss from investing in the stock five years ago

While institutions own 21% of Perfect Corp. (NYSE:PERF), public companies are its largest shareholders with 41% ownership

Simply Wall St.

a year ago

While institutions own 21% of Perfect Corp. (NYSE:PERF), public companies are its largest shareholders with 41% ownership

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

GlobeNewswire

a year ago

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

GlobeNewswire

a year ago

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

Insider Sell Alert: COO Jason Dale Sells 40,000 Shares of Vital Farms Inc (VITL)

GuruFocus.com

a year ago

Insider Sell Alert: COO Jason Dale Sells 40,000 Shares of Vital Farms Inc (VITL)

Sprott Focus Trust, Inc. (Nasdaq-FUND) Declares Fourth Quarter Common Stock Distribution of $0.1270 Per Share

GlobeNewswire

a year ago

Sprott Focus Trust, Inc. (Nasdaq-FUND) Declares Fourth Quarter Common Stock Distribution of $0.1270 Per Share

15 US States with the Most Debt Per Capita

Insider Monkey

a year ago

15 US States with the Most Debt Per Capita

Share on Social Networks: